Zafgen Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
35,517.00
115,462.00
185,079.00
129,194.00
102,052.00
118,066
Total Accounts Receivable
1,617.00
391.00
1,323.00
347.00
946.00
1,536
Other Current Assets
224.00
1,345.00
1,708.00
1,358.00
1,927.00
1,728
Total Current Assets
37,358.00
117,198.00
188,110.00
130,899.00
104,925.00
121,330
Net Property, Plant & Equipment
37.00
79.00
902.00
661.00
528.00
375
Other Assets
743.00
242.00
94.00
61.00
57.00
57
Total Assets
38,138.00
117,519.00
189,106.00
131,621.00
105,510.00
121,762
ST Debt & Current Portion LT Debt
-
1,381.00
2,936.00
3,589.00
-
Other Current Liabilities
2,915.00
5,520.00
13,607.00
6,305.00
7,293.00
Total Current Liabilities
2,915.00
6,901.00
16,543.00
9,894.00
7,293.00
Long-Term Debt
-
6,177.00
3,453.00
-
20,000.00
Total Liabilities
2,915.00
13,078.00
19,996.00
9,894.00
27,293.00
Common Equity (Total)
68,574.00
104,441.00
169,110.00
121,727.00
78,217.00
Total Shareholders' Equity
35,223.00
104,441.00
169,110.00
121,727.00
78,217.00
Total Equity
35,223.00
104,441.00
169,110.00
121,727.00
78,217.00
Liabilities & Shareholders' Equity
38,138.00
117,519.00
189,106.00
131,621.00
105,510.00
Preferred Stock (Carrying Value)
103,797.00
-
-
-
-

About Zafgen

View Profile
Address
175 Portland Street
Boston Massachusetts 02114
United States
Employees -
Website http://www.zafgen.com
Updated 07/08/2019
Zafgen, Inc. is a biopharmaceutical company, which is engages in the development of therapeutics for both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders. It offers the ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of type 2 diabetes. The company was founded on November 22, 2005 and is headquartered in Boston, MA.